Atrium Therapeutics, Inc. (RNA) Balance Sheet

As of 2026-06-30 (10-Q), Atrium Therapeutics, Inc. (RNA) reported total assets of $280.5M, total liabilities of $65.9M and shareholders' equity of $214.6M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $72.3M.

Source: SEC EDGAR filings · read by EquiReason

RNAAtrium Therapeutics, Inc.Follow RNA — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 140.3M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 9 Nov, in 16 days

Balance-sheet dates are not available for this company yet.

USD millions · SEC XBRL

Atrium Therapeutics, Inc. — questions

How much cash does Atrium Therapeutics, Inc. have?: $72.3M in cash and cash equivalents as of 2026-06-30.
What are Atrium Therapeutics, Inc.'s total assets?: $280.5M as of 2026-06-30.
What is Atrium Therapeutics, Inc.'s shareholders' equity?: $214.6M as of 2026-06-30.

Every figure on this page comes from Atrium Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.